Westlake Biopartners Opportunity Fund I, L.P. bought KYTX once, on Dec 18, 2025
10% owner at Kyverna Therapeutics, Inc.
SEC CIK 0001811946 · Filings on SEC.gov ↗
Westlake Biopartners Opportunity Fund I, L.P.'s record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
1 filing since Dec 2025, newest first
About Westlake Biopartners Opportunity Fund I, L.P.
Westlake Biopartners Opportunity Fund I, L.P. is a venture capital fund managed by Westlake BioPartners, a life science venture capital firm based in Westlake Village, California, focused on incubating and investing in early-stage biotechnology companies to develop life-saving medicines.( Established as part of Westlake BioPartners' ecosystem, the fund supports entrepreneurs with hands-on guidance from ideation through clinical and commercial stages, leveraging the firm's deep ties to the Los Angeles biotech community.(
Westlake BioPartners, founded in September 2018, has raised over $1.3 billion across its funds, including a $450 million third fund launched in July 2023, and has created more than 20 companies, such as Capsida Biotherapeutics, Latigo Biotherapeutics, and ACELYRIN, INC.( The firm is led by managing directors Beth Seidenberg, M.D., Mira Chaurushiya, Ph.D., and David Allison, Ph.D., who bring extensive expertise in biotech investing and company-building.( As a corporate insider, Westlake Biopartners Opportunity Fund I, L.P. (CIK: 0001811946) recently engaged in trading activity at Kyverna Therapeutics, Inc. (KYTX), holding approximately 10% stake.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.